Recipharm buys into an India CMO; PCI rebrands;

> Contract drugmaker Recipharm is paying about $105 million for a majority stake of Indian manufacturer Nitin Lifesciences. News

> PCI, fresh off acquisitions of Penn Pharma and Biotec, has rebranded itself. Item

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.